Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Search results

Showing results for

Today University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%.

Phase 3 human trials of Oxford coronavirus vaccine © John Cairns

Sign up for course news and updates

Sign up to our newsletter to receive the latest news, insights and events directly to your inbox.

Participant Interest Form

Online induction completion

Join our research community

Join the Restore-B research community for breast reconstruction

SITU Expression of Interest Form

Categories

Similar stories